$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
PARP抑制剂对晚期前列腺癌的适应症
2025-10-19 11:44:20
Check Details
联合免疫疗法给晚期前列腺癌患者带来益处
2025-10-19 11:44:20
Check Details
FDA授予EPI-7386治疗mCRPC的快速审核资格
2025-10-19 11:44:20
Check Details
奥拉帕尼显著提高mCRPC亚组的总生存期
2025-10-19 11:44:20
Check Details
新型BiTE免疫肿瘤药物治疗mCRPC的早期疗效观察
2025-10-19 11:44:20
Check Details
奥拉帕尼获批用于治疗转移性去势抵抗性前列腺癌
2025-10-19 11:44:20
Check Details
恩杂鲁胺多少钱
2025-10-19 11:44:20
Check Details
恩杂鲁胺效果怎么样
2025-10-19 11:44:20
Check Details
恩杂鲁胺说明书
2025-10-19 11:44:20
Check Details
恩杂鲁胺的图片
2025-10-19 11:44:20
Check Details
恩杂鲁胺有效果吗
2025-10-19 11:44:20
Check Details
国内恩杂鲁胺多少钱一瓶
2025-10-19 11:44:20
Check Details
1
2
...
1477
1478
1479
1480
1481
1482
1483
...
4163
4164
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
2
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
3
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
4
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
5
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
6
Selumetinib and KRAS Mutations: Where the MEK Inhibitor Actually Fits
7
Erdafitinib in Lung Squamous Cell Carcinoma: Indication Boundaries and FGFR Interpretation
8
Daraxonrasib (Rasonque): Chemical Identity and RAS Tri-Complex Mechanism
9
Tamoxifen and Feeling Older: Managing Hot Flashes, Fatigue, and Skin Changes
10
FDA Approves Pembrolizumab for TMB-H Solid Tumors: Threshold ≥13 mut/Mb, KEYNOTE-158 Data
11
Capmatinib for METex14 NSCLC: Test First, Monitor Toxicity
12
Ribociclib Still Allows Recurrence: HR+/HER2- Adjuvant and Advanced Use